Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foamix Pharmaceuticals Ltd.

www.foamix.co.il

Latest From Foamix Pharmaceuticals Ltd.

Keeping Track: US FDA Receives Submissions Galore As Year Ends

A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Drug Review Regulation

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.

 

Research & Development Dermatology

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies

Foamix's Minocycline Foam: A Game Changer In Severe Acne?

A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.

Clinical Trials Dermatology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Foamix Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Foamix Pharmaceuticals Ltd.
  • Senior Management
  • David Domzalski, CEO
    Ilan Hadar, CFO
    Mitchell Shirvan, PhD, VP, Innovation & Disc.
    Yohan Hazot, MSc, VP, Pharmaceutical Dev.
    Russell Elliott, PhD, VP, Drug Dev.
    Iain Stuart, PhD, SVP, R&D
    Alvin Howard, VP, Reg. Affairs
  • Contact Info
  • Foamix Pharmaceuticals Ltd.
    Phone: (972) 8 9316233
    Weizmann Science Park
    2 Holzman St.
    Rehovot, 7670402
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register